Chris: I agree with the point about them not having in-house diagnostics expertise. However, I keep thinking about the multiple times GC said they may not need a RS. If he was serious (and that's certainly debatable), they would need to sell the DX division at a hefty price because it doesn't appear the market is assigning much value to the therapeutics division at this time.

Typically, one orphan designation results in a material bump to pps. We didn't see any for the MANF RP orphan. We also have two phase II drugs (Elto, ESS) that should be valued much higher than the market is valuing them.

Perhaps GC and company are thinking that selling the DX division could be the catalyst to uplist without a RS.